<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626674</url>
  </required_header>
  <id_info>
    <org_study_id>SRP-9001-103</org_study_id>
    <nct_id>NCT04626674</nct_id>
  </id_info>
  <brief_title>A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From SRP-9001 in Participants With Duchenne Muscular Dystrophy (DMD)</brief_title>
  <acronym>ENDEAVOR</acronym>
  <official_title>An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sarepta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label gene transfer therapy study evaluating the safety of and expression&#xD;
      from SRP-9001 in participants with DMD over 260 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Change From Baseline in Quantity of Micro-Dystrophin Protein Expression at Week 12, as Measured by Western Blot</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vector Shedding, Measured in Urine, Saliva, and Stool Samples Post-Infusion</measure>
    <time_frame>Day 1 up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Antibody Titers to Recombinant Adeno-Associated Virus Serotype rh74 (rAAVrh74)</measure>
    <time_frame>Day 2 up to Week 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) of Special Interest</measure>
    <time_frame>Baseline up to Week 260</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quantity of Micro-Dystrophin Protein Expression at Week 12, as Measured by Immunofluorescence (IF) Fiber Intensity</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quantity of Micro-Dystrophin Expression at Week 12, as Measured by IF Percent Dystrophin Positive Fibers (PDPF)</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <arm_group>
    <arm_group_label>SRP-9001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single intravenous (IV) infusion of SRP-9001 on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SRP-9001</intervention_name>
    <description>Single IV infusion of SRP-9001</description>
    <arm_group_label>SRP-9001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cohort 1 only: Is ambulatory, and ≥4 to &lt;8 years of age at the time of Screening.&#xD;
&#xD;
          -  Cohort 2 only: Is ambulatory, and ≥8 to &lt;18 years of age at the time of Screening.&#xD;
&#xD;
          -  Cohort 3 only: Non-ambulatory per protocol specified criteria.&#xD;
&#xD;
          -  Cohort 4 only: Is ambulatory, and ≥3 to &lt;4 years of age at the time of Screening.&#xD;
&#xD;
          -  Definitive diagnosis of DMD based on documented clinical findings and prior genetic&#xD;
             testing.&#xD;
&#xD;
          -  Ability to cooperate with motor assessment testing.&#xD;
&#xD;
          -  Cohorts 1, 2, and 3 only: Stable dose equivalent of oral corticosteroids for at least&#xD;
             12 weeks before screening and the dose is expected to remain constant (except for&#xD;
             modifications to accommodate changes in weight) throughout the first year of the&#xD;
             study.&#xD;
&#xD;
          -  Cohort 4: Do not yet require use of chronic steroids for treatment of their DMD, in&#xD;
             the opinion of the Investigator, and are not receiving steroids at the time of&#xD;
             Screening.&#xD;
&#xD;
          -  rAAVrh74 antibody titers are not elevated as per protocol-specified requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a concomitant illness, autoimmune disease, chronic drug treatment, and/or&#xD;
             cognitive delay/impairment that in the opinion of the Investigator creates unnecessary&#xD;
             risks for gene transfer.&#xD;
&#xD;
          -  Exposure to gene therapy, investigational medication, or any treatment designed to&#xD;
             increase dystrophin expression within protocol specified time limits.&#xD;
&#xD;
          -  Abnormality in protocol-specified diagnostic evaluations or laboratory tests.&#xD;
&#xD;
        Other inclusion/exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>Gene-Delivery</keyword>
  <keyword>DMD</keyword>
  <keyword>Ambulatory</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Micro-dystrophin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

